Drug Trial Radar · NCT06402123
A Phase 2b Study of Zagociguat in Patients With MELAS
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Sep 10, 2024
Primary completion
Jun 29, 2026
Study completion Jun 29, 2026
Sponsor
- Lead sponsor
- Tisento TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.
Conditions
- Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions
zagociguat 15mgDrug
Once-daily oral tablets
zagociguat 30mgDrug
Once-daily oral tablets
PlaceboDrug
Once-daily oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- • PROMIS Fatigue MELAS Short Form scores• Groton Maze Learning Test scores • International Digit Symbol Substitution Test scoresTime frame: Weeks 9 through 12 of each treatment period
- Incidence of Treatment-emergent Adverse Events (TEAEs)Time frame: Weeks 1 through washout for treatment period 1 and Weeks 1 through follow-up for treatment period 2
Locations
20 sites in 6 countries. Site status is shown where the registry gives one.
UC San Diego - Altman Clinical and Translational Research Institute
La Jolla, California
Children's Hospital of Colorado
Aurora, Colorado
Rare Disease Research
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
Columbia University Irving Medical Center
New York, New York
Mount Sinai - Ichan School of Medicine
New York, New York
Akron Children's Hospital
Akron, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Baylor College of Medicine
Houston, Texas
University of Texas Medical School at Houston
Houston, Texas
Neuroscience Research Australia
Sydney, New South Wales, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
Shared Health/University of Manitoba
Winnipeg, Manitoba, Canada
McMaster University Medical Center
Hamilton, Ontario, Canada
University Hospital Bonn
Bonn, Germany
Ludwig-Maximilians-University of Munich
Munich, Germany
Neurologic Institute Carlo Besta of Milan
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
Newcastle University
Newcastle upon Tyne, United Kingdom
UCL Queen Square Institute of Neurology
London, London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.